Nxera Pharma Earns $10M Milestone as Neurocrine Wins FDA Acceptance for Alzheimer’s Phase 2 Study
Tokyo, Japan and Cambridge, UK — August 26, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences...
Neurocrine Biosciences
Advertisement
Neurocrine Initiates Phase 2 Trial of Crinecerfont in Children Under 4 with Classic CAH
SAN DIEGO, July 1, 2026 Neurocrine Biosciences announced the initiation of a Phase 2 clinical trial evaluating crinecerfont (CRENESSITY®)...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Neurocrine Reports Two-Year CRENESSITY Data Showing Improved Growth in Pediatric CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
Neurocrine Biosciences Reports New INGREZZA Data in Tardive Dyskinesia
SAN DIEGO, June 8, 2026 Neurocrine Biosciences announced new clinical findings demonstrating the long-term effectiveness of INGREZZA® (valbenazine) capsules...
Advertisements
Galmed to Acquire Colospan in Major GI MedTech Expansion
RAMAT GAN, Israel – June 8, 2026 Galmed Pharmaceuticals has entered into a definitive agreement to acquire Colospan Ltd.,...
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Neurocrine Defines TDIS Threshold for TD Treatment Impact
SAN DIEGO, California, April 29, 2026 Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of...
Neurocrine Shows CRENESSITY Sustains CAH Control Data
San Diego, USA – April 22, 2026 In a major advancement for endocrine disorder management, Neurocrine Biosciences has unveiled...
GlycoNex Secures PMDA Nod for GNX1021 Phase 1 Trial
NEW TAIPEI CITY, TAIWAN, April 14, 2026 GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency...
Advertisement
